Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):370-381. doi: 10.1182/hematology.2023000438.ABSTRACTPatients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of those patients. However, with the approval of several novel bispecific monoclonal antibody (BsAb) therapies with considerable activity in R/R aggressive large B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions regarding how to sequence CAR-T and BsAb therapies based on patient- and disease-related factors. In this review, we compare CAR-T and BsAb therapies for R/R LBCL, highlighting data on the efficacy and toxicity of each treatment paradigm, and provide a roadmap for sequencing these highly effective therapies.PMID:38066907 | PMC:PMC10727048 | DOI:10.1182/hematology.2023000438
Source: Hematology ASH Education Program - Category: Hematology Authors: Source Type: research